Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer

Citation
F. Koga et al., Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer, JPN J CANC, 91(4), 2000, pp. 416-423
Citations number
30
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
JAPANESE JOURNAL OF CANCER RESEARCH
ISSN journal
0910-5050 → ACNP
Volume
91
Issue
4
Year of publication
2000
Pages
416 - 423
Database
ISI
SICI code
0910-5050(200004)91:4<416:NPPIIA>2.0.ZU;2-J
Abstract
The relationship between clinical response to DNA-damaging drugs and p53 an d p21 status in patients with locally advanced transitional cell carcinoma (TCC) of the bladder was assessed. The response to intraarterial chemothera py (IAC) comprising 100 mg/m(2) of cisplatin (CDDP) and 40 mg/m2 of pirarub icin (THP) and the prognosis were assessed in 23 patients (the mean follow- up period was 19 months). The p53 gene status of tumors was analyzed at exo ns 5-8 using polymerase chain reaction-single strand conformation polymorph ism analysis in 19 patients, and paraffin-embedded tumor sections were immu nostained for p53 and p21 in 23 patients. The overall objective response ra te (incidence of good responders) was 70%. The negative p53 group (n=17) sh owed a significantly higher objective response rate than the positive p53 g roup (n=6,) (82% vs. 33%; P=0.045), The p53 gene status or p21 staining sta tus was not significantly associated with responsiveness. When the p53 and p21 immunostaining results were combined, good responders were more accurat ely predicted than by p53 staining status alone; the negative p53/positive p21 group (n=12) showed an objective response rate of 92%, which was signif icantly higher than that of the positive p53 and/or negative p21 group (45% , n=11) (P=0.027). Cause-specific survival of the negative p53 group was si gnificantly superior to that of the positive p53 group (P=0.015). Negative p53/positive p21 immunostaining is a possible predictor of favorable chemot herapeutic response in patients with TCC of the bladder.